title: How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
abstract: The management of bleeds in patients with haemophilia A or B complicated by inhibitors is complex. Recombinant activated Factor VII (rFVIIa; NovoSeven RT) is an established therapy in these patients. To develop a consensus-based guide on the practical usage of rFVIIa in haemophilia complicated by inhibitors, nine expert haemophilia specialists from Australia and New Zealand developed practice points on the usage of rFVIIa, based on their experience and supported by published data. Practice points were developed for 13 key topics: control of acute bleeding; prophylaxis; surgical prophylaxis; control of breakthrough bleeding during surgery or treatment of acute bleeds; paediatric use; use in elderly; intracranial haemorrhage; immune tolerance induction; difficult bleeds; clinical monitoring of therapy; laboratory monitoring of therapy; concomitant antifibrinolytic medication; practical dosing. Access to home therapy with rFVIIa is important in allowing patients to administer treatment early in bleed management. In adults, 90-120 μg/kg is the favoured starting dose in most settings. Initial dosing using 90-180 μg/kg is recommended for children due to the effect of age on the pharmacokinetics of rFVIIa. In the management of acute bleeds, 2-hourly dosing is appropriate until bleeding is controlled, with concomitant antifibrinolytic medication unless contraindicated. The practice points provide guidance on the usage of rFVIIa for all clinicians involved in the management of haemophilia complicated by inhibitors.
authors.affiliation: Department of Haematology and Oncology, Royal Children's Hospital, Brisbane, Queensland, Australia. simon_brown@health.qld.gov.au
authors.forename: S A
authors.initials: SA
authors.lastname: Brown
authors.forename: C
authors.initials: C
authors.lastname: Barnes
authors.forename: J
authors.initials: J
authors.lastname: Curtin
authors.forename: S
authors.initials: S
authors.lastname: Dunkley
authors.forename: P
authors.initials: P
authors.lastname: Ockelford
authors.forename: J
authors.initials: J
authors.lastname: Phillips
authors.forename: J
authors.initials: J
authors.lastname: Rowell
authors.forename: M
authors.initials: M
authors.lastname: Smith
authors.forename: H
authors.initials: H
authors.lastname: Tran
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D015942:Factor VIIa / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000150:complications* / Q000191:economics / Q000276:immunology; D002836:Hemophilia B / Q000150:complications* / Q000191:economics / Q000276:immunology; D006470:Hemorrhage / Q000188:drug therapy* / Q000191:economics / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007518:Isoantibodies / Q000276:immunology*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics / Q000276:immunology / Q000627:therapeutic use; D013923:Thromboembolism / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000933:Antifibrinolytic Agents; D007518:Isoantibodies; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa